Sanofi (SNY) highlights Vicebio acquisition and China approvals for Qfitlia, Cablivi

Rhea-AI Filing Summary

Sanofi reports two key developments from December 2025. The company completed its acquisition of Vicebio, as described in a press release dated December 4, 2025.

A second press release dated December 11, 2025 reports that Sanofi’s medicines Qfitlia and Cablivi were approved in China, expanding care options for patients with rare diseases in that market.

Insights

Healthcare industry analyst

Sanofi reports completing a biotech acquisition and gaining China approvals for two rare-disease drugs.

Sanofi highlights two December developments: it completed the acquisition of Vicebio, and it reported that Qfitlia and Cablivi received approval in China. The acquisition indicates continued investment in external innovation, while the China approvals extend the reach of its rare-disease treatments.

Regulatory approval in China for Qfitlia and Cablivi means these medicines can be offered to patients in that country, supporting Sanofi’s rare-disease franchise internationally. The detailed financial terms of the Vicebio deal and the commercial scope of the China launches are described in the press releases dated December 4, 2025 and December 11, 2025, which accompany this report.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of December 2025

Commission File Number: 001-31368

SANOFI

(Translation of registrant’s name into English)

46, avenue de la Grande Armée, 75017 Paris, FRANCE

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

1

In December 2025, Sanofi published the press releases attached hereto as Exhibits 99.1 and 99.2 which are incorporated herein by reference.

Exhibit Index

Exhibit No.		Description
Exhibit 99.1		Press Release dated December 4, 2025: Sanofi completes acquisition of Vicebio
Exhibit 99.2		Press Release dated December 11, 2025: Sanofi’s Qfitlia and Cablivi approved in China, expanding care for rare diseases

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: December 12, 2025						SANOFI
				By		/s/ Alexandra Roger
						Name: Alexandra Roger
						Title: Head of Legal Corporate & Finance

3

FAQ

What did Sanofi (SNY) report in its December 2025 submission?

Sanofi reported that it completed the acquisition of Vicebio and that its medicines Qfitlia and Cablivi were approved in China, expanding care for rare diseases.

Which company did Sanofi (SNY) acquire according to this report?

Sanofi completed the acquisition of Vicebio, as described in a press release dated December 4, 2025 attached to the report as Exhibit 99.1.

Which Sanofi (SNY) medicines were approved in China?

The report states that Qfitlia and Cablivi were approved in China, expanding care options for patients with rare diseases there, as detailed in Exhibit 99.2.

How does this filing relate to Sanofi (SNY) rare disease treatments?

It notes that Qfitlia and Cablivi, two Sanofi medicines, received approval in China, which the company describes as expanding care for rare diseases in that market.

What documents are attached to this Sanofi (SNY) report?

Two press releases are attached: Exhibit 99.1 titled “Sanofi completes acquisition of Vicebio” and Exhibit 99.2 titled “Sanofi’s Qfitlia and Cablivi approved in China, expanding care for rare diseases”.